PMID- 8559303
OWN - NLM
STAT- MEDLINE
DCOM- 19960226
LR  - 20190512
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 37
IP  - 4
DP  - 1995 Oct
TI  - Effects of brain-derived neurotrophic factor on 
      1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
PG  - 733-9; discussion 739-41
AB  - The effects of intrathecal infusion of brain-derived neurotrophic factor (BDNF) 
      were examined in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced 
      parkinsonian model in monkeys. Nine Japanese monkeys were divided randomly into 
      three groups, an untreated control (n = 3), a BDNF group (n = 3), and a non-BDNF 
      group (n = 3). Animals in the BDNF group received continuous intrathecal infusion 
      of 10 ml of cell culture medium containing 10 micrograms of BDNF protein; the 
      non-BDNF group received intrathecal infusion of the same culture medium without 
      BDNF. To induce parkinsonian syndromes, a total of 1 mg/kg 
      1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was administered intravenously to 
      each monkey in both the BDNF and non-BDNF groups. The neurological signs in the 
      monkeys were monitored for 2 weeks and were scored according to the monkey 
      parkinsonism rating scale; histological changes in the substantia nigra were 
      evaluated after the 2-week observation period. The BDNF-treated animals remained 
      asymptomatic during the 1st week and showed mild parkinsonism during the 2nd 
      week, whereas the non-BDNF group showed typical parkinsonian syndrome during the 
      1st week, with deterioration in the 2nd week. Histological damage in the 
      substantia nigra correlated well with the clinical features. Severe neuronal cell 
      loss in the substantia nigra was observed in animals with severe parkinsonism 
      (those in the non-BDNF group), whereas significantly less damage was observed in 
      this region in the BDNF group.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Tsukahara, T
AU  - Tsukahara T
AD  - Department of Neurosurgery, National Cardiovascular Center, Osaka, Japan.
FAU - Takeda, M
AU  - Takeda M
FAU - Shimohama, S
AU  - Shimohama S
FAU - Ohara, O
AU  - Ohara O
FAU - Hashimoto, N
AU  - Hashimoto N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Nerve Tissue Proteins)
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
SB  - IM
MH  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MH  - Animals
MH  - Brain/*drug effects/pathology/physiopathology
MH  - Brain-Derived Neurotrophic Factor
MH  - Macaca
MH  - Nerve Degeneration/drug effects/physiology
MH  - Nerve Growth Factors/*pharmacology
MH  - Nerve Tissue Proteins/*pharmacology
MH  - Neurologic Examination/drug effects
MH  - Parkinson Disease, Secondary/chemically induced/pathology/*physiopathology
MH  - Substantia Nigra/drug effects/pathology/physiopathology
MH  - Tyrosine 3-Monooxygenase/metabolism
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1227/00006123-199510000-00018 [doi]
PST - ppublish
SO  - Neurosurgery. 1995 Oct;37(4):733-9; discussion 739-41. doi: 
      10.1227/00006123-199510000-00018.